Use of retinoic acid/aldehyde dehydrogenase pathway as potential targeted therapy against cancer stem cells
A large number of studies have investigated possible drug resistance mechanisms of cancer cells and suggested strategies to overcome it. In this review, we outline the role and function of aldehyde dehydrogenase (ALDH) activity in multiple cellular functions and in cancer stem cells (CSCs) and focus on the role of retinoic acid (RA), one of the products of ALDH isozymes. We discuss our observation that ATRA and other RAs can suppress ALDH activity and decrease different ALDH isozyme proteins and result in detrimental effects on cell proliferation, invasion and chemotherapy sensitivity. We review the known uses of different RAs in the treatment of cancers. We review the use of RAs in combination with chemo-/radiotherapy and the major signaling pathways affected in different tumor types. We provide follow-up on studies that may have used our prior observation with the aim of targeting the CSCs. We conclude with summary of the findings and potential impact of published studies on future use of RAs in the targeting of CSCs and drug resistance.
KeywordsRetinoic acid Aldehyde dehydrogenase Cancer stem cells Chemotherapy
Compliance with ethical standards
Conflict of interest
The authors have no conflict of interest to declare.
- 2.Vasiliou V, Nebert DW (2005) Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family. Hum Genom 2:138–143Google Scholar
- 29.Warrier S, Bhuvanalakshmi G, Arfuso F et al (2014) Cancer stem-like cells from head and neck cancers are chemosensitized by the Wnt antagonist, sFRP4, by inducing apoptosis, decreasing stemness, drug resistance and epithelial to mesenchymal transition. Cancer Gene Ther 21:381–388CrossRefPubMedGoogle Scholar
- 38.Moreb JS, Ucar D, Han S et al (2012) The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance. Chem Biol Interact 195:52–60CrossRefPubMedGoogle Scholar
- 59.Moro M, Bertolini G, Pastorino U et al (2015) Combination treatment with all-trans retinoic acid prevents cisplatin-induced enrichment of CD133+ tumor-initiating cells and reveals heterogeneity of cancer stem cell compartment in lung cancer. J Thorac Oncol 10:1027–1036CrossRefPubMedPubMedCentralGoogle Scholar
- 70.Arrieta O, González-De la Rosa CH, Aréchaga-Ocampo E et al (2010) Randomized phase II trial of All-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer. J Clin Oncol 28:3463–3471CrossRefPubMedGoogle Scholar
- 71.Burnett AK, Hills RK, Green C et al (2010) The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood 115:948–956CrossRefPubMedGoogle Scholar